scholarly journals Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease

2014 ◽  
Vol 40 (1) ◽  
pp. 135-142 ◽  
Author(s):  
Anne Gerschütz ◽  
Helmut Heinsen ◽  
Edna Grünblatt ◽  
Anne Kristin Wagner ◽  
Jasmin Bartl ◽  
...  
2018 ◽  
Vol 15 (4) ◽  
pp. 355-362 ◽  
Author(s):  
Vincenza Rita Lo Vasco

Background: During aging and in age-associated disorders, such as Alzheimer's Disease (AD), learning abilities decline. Probably, disturbances in signal transduction in brain cells underlie the cognitive decline. The phosphorylation/dephosphorylation imbalance occurring in degenerating neurons was recently related to abnormal activity of one or more signal transduction pathways. AD is known to be associated with altered neuronal Ca<sup>2+</sup> homeostasis, as Ca<sup>2+</sup> accumulates in affected neurons leading to functional impairment. It is becoming more and more evident the involvement of signal transduction pathways acting upon Ca<sup>2+</sup> metabolism and phosphorylation regulation of proteins. A growing interest raised around the role of signal transduction systems in a number of human diseases including neurodegenerative diseases, with special regard to the systems related to the phosphoinositide (PI) pathway and AD. The PI signal transduction pathway plays a crucial role, being involved in a variety of cell functions, such as hormone secretion, neurotransmitter signal transduction, cell growth, membrane trafficking, ion channel activity, cytoskeleton regulation, cell cycle control, apoptosis, cell and tissue polarity, and contributes to regulate the Ca<sup>2+</sup> levels in the nervous tissue. Conclusion: A number of observations indicated that PI-specific phospholipase C (PLC) enzymes might be involved in the alteration of neurotransmission. To understand the role and the timing of action of the signalling pathways recruited during the brain morphology changes during the AD progression might help to elucidate the aetiopathogenesis of the disease, paving the way to prognosis refinement and/or novel molecular therapeutic strategies.


Molecules ◽  
2018 ◽  
Vol 23 (12) ◽  
pp. 3351 ◽  
Author(s):  
Veronika Furlan ◽  
Janez Konc ◽  
Urban Bren

Research efforts are placing an ever increasing emphasis on identifying signal transduction pathways related to the chemopreventive activity of curcumin. Its anticarcinogenic effects are presumably mediated by the regulation of signaling cascades, including nuclear factor κB (NF-κB), activator protein 1 (AP-1), and mitogen-activated protein kinases (MAPK). By modulating signal transduction pathways, curcumin induces apoptosis in malignant cells, thus inhibiting cancer development and progression. Due to the lack of mechanistic insight in the scientific literature, we developed a novel inverse molecular docking protocol based on the CANDOCK algorithm. For the first time, we performed inverse molecular docking of curcumin into a collection of 13,553 available human protein structures from the Protein Data Bank resulting in prioritized target proteins of curcumin. Our predictions were in agreement with the scientific literature and confirmed that curcumin binds to folate receptor β, DNA (cytosine-5)-methyltransferase 3A, metalloproteinase-2, mitogen-activated protein kinase 9, epidermal growth factor receptor and apoptosis-inducing factor 1. We also identified new potential protein targets of curcumin, namely deoxycytidine kinase, NAD-dependent protein deacetylase sirtuin-1 and -2, ecto-5′-nucleotidase, core histone macro-H2A.1, tyrosine-protein phosphatase non-receptor type 11, macrophage colony-stimulating factor 1 receptor, GTPase HRas, aflatoxin B1 aldehyde reductase member 3, aldo-keto reductase family 1 member C3, amiloride-sensitive amine oxidase, death-associated protein kinase 2 and tryptophan-tRNA ligase, that may all play a crucial role in its observed anticancer effects. Moreover, our inverse docking results showed that curcumin potentially binds also to the proteins cAMP-specific 3′,5′-cyclic phosphodiesterase 4D and 17-β-hydroxysteroid dehydrogenase type 10, which provides a new explanation for its efficiency in the treatment of Alzheimer’s disease. We firmly believe that our computational results will complement and direct future experimental studies on curcumin’s anticancer activity as well as on its therapeutic effects against Alzheimer’s disease.


1995 ◽  
Vol 149-150 (1) ◽  
pp. 287-292 ◽  
Author(s):  
Christopher J. Fowler ◽  
Richard F. Cowburn ◽  
Anita Garlind ◽  
Bengt Winblad ◽  
Cora O'Neill

Neurosignals ◽  
2002 ◽  
Vol 11 (5) ◽  
pp. 235-235 ◽  
Author(s):  
Mark A. Smith ◽  
Xiongwei Zhu ◽  
George Perry

1999 ◽  
Vol 20 (2-3) ◽  
pp. 93-109 ◽  
Author(s):  
René Etcheberrigaray ◽  
Seetha Bhagavan

The Analyst ◽  
2020 ◽  
Vol 145 (8) ◽  
pp. 2925-2936
Author(s):  
Son T. Le ◽  
Michelle A. Morris ◽  
Antonio Cardone ◽  
Nicholas B. Guros ◽  
Jeffery B. Klauda ◽  
...  

Commercially sourced silicon field-effect transistors enable sensitive measurements of small therapeutic molecules that regulate enzymes implicated in Alzheimer's disease.


Sign in / Sign up

Export Citation Format

Share Document